Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins
A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The laboratory-created monoclonal antibody, called IC14, binds to a human protein, CD14, that is found on the surface of immune cells circulating in the blood and airway fluid and that also circulates as a stand-alone protein. CD14 helps immune cells recognize pathogens and injured or dying cells, alerting the immune system to danger and prompting it to respond.
By OLIVIA DAVIES, ABC News
(NEW YORK) Federal health officials on Tuesday ordered a temporary stop on administering COVID-19 vaccine produced by Johnson & Johnson after reports of six people experiencing a blood clotting disorder.
The Centers for Disease Control and Prevention and the Food and Drug Administration said in a joint statement the agencies were recommending a pause while more data pertaining to the single-shot vaccine is collected and reviewed.
Nearly 7 million people in the U.S. have received J&J shots, and roughly 9 million more doses have been distributed for future use, according to CDC data.
There have been no blood clotting cases reported so far tied to the Pfizer or Moderna vaccines, but if you ve received the J&J single-dose vaccine and are concerned over potential side effects here s what you need to know.
Christopher Gebhard of North Cornwall Township was not considering a run for public service 12 months ago, but the COVID-19 pandemic changed all that. (I m) in the commercial insurance business, and we have roughly 1,000 commercial clients, and I ve basically spent the year seeing a good majority of those struggle to survive with the draconian lockdowns from the governor, he said.
The president and CEO of Hoaster Gebhard & Co., an insurance and risk management firm, was chosen by the local GOP to run in the May 18 special election to fill the 48th Senate District seat. The district includes Lebanon County and parts of York and Dauphin counties.
J&J vaccine remains on pause as CDC panel requests more information msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
HIN
A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The laboratory-created monoclonal antibody, called IC14, binds to a human protein, CD14, that is found on the surface of immune cells circulating in the blood and airway fluid and that also circulates as a stand-alone protein. CD14 helps immune cells recognize pathogens and injured or dying cells, alerting the immune system to danger and prompting it to respond.